tiprankstipranks
Trending News
More News >
NEUSOFT XIKANG HOLDINGS INC. (HK:9686)
:9686
Hong Kong Market
Advertisement

NEUSOFT XIKANG HOLDINGS INC. (9686) AI Stock Analysis

Compare
0 Followers

Top Page

HK:9686

NEUSOFT XIKANG HOLDINGS INC.

(9686)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
HK$1.00
▲(9.89% Upside)
The overall stock score is primarily impacted by weak financial performance and poor valuation metrics. The technical analysis suggests a bearish trend, although the RSI indicates potential for a rebound. Improvements in free cash flow provide a slight positive note, but the company's high leverage and negative profitability remain significant concerns.

NEUSOFT XIKANG HOLDINGS INC. (9686) vs. iShares MSCI Hong Kong ETF (EWH)

NEUSOFT XIKANG HOLDINGS INC. Business Overview & Revenue Model

Company DescriptionXikang Cloud Hospital Holdings, Inc. engages in the development of a city-specific cloud hospital platform. It operates through the following segments: Cloud Hospital Platform Services, Internet Medical Services, Health Management Services, and Smart Healthcare Products. The Cloud Hospital Platform Services segment offers technology solutions to local governments, medical institutions, and insurers. The Internet Medical Services segment includes online hospital, remote medical, smart family doctor, and internet home care services. The Health Management Services segment consists of comprehensive health management and chronic disease management services. The Smart Healthcare Products segment sells smart healthcare products to local governments, primary medical institutions, corporations, and individuals. The company was founded on May 12, 2011 and is headquartered in Shanghai, China.
How the Company Makes MoneyNeusoft Xikang Holdings Inc. generates revenue through a diversified business model centered around its digital health solutions. The company earns money from the sale and licensing of its proprietary healthcare platforms and software solutions to hospitals, clinics, and other healthcare providers. Additionally, revenue is generated from the sale of medical devices and equipment. Neusoft Xikang also offers health management and consulting services, which provide recurring income streams. The company has established strategic partnerships with healthcare institutions and technology firms, further enhancing its market reach and revenue potential. Key factors contributing to its earnings include its ability to innovate in digital health and its strong presence in the rapidly growing healthcare technology market.

NEUSOFT XIKANG HOLDINGS INC. Financial Statement Overview

Summary
The financial performance is weak, with declining revenues and persistent losses. Despite improvements in cash flow and equity position, the company faces significant operational challenges and needs to strengthen its revenue base.
Income Statement
45
Neutral
The company has faced declining revenues with a negative revenue growth rate of -6.73% from 2023 to 2024. Margins are weak, with a gross profit margin of 29.41% and a net profit margin of -16.56% in 2024, indicating significant losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.
Balance Sheet
40
Negative
The balance sheet shows a moderate debt-to-equity ratio of 1.58 in 2024, indicating reliance on debt financing. However, the equity position improved from negative in previous years to positive in 2024. The equity ratio is 28.83%, suggesting a relatively low equity base compared to total assets.
Cash Flow
55
Neutral
The company achieved positive operating cash flow in 2024, a significant improvement from negative cash flows in prior years. The free cash flow to net income ratio is positive, indicating better cash generation relative to net losses. However, cash flow stability remains a concern given historical volatility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue500.89M501.50M537.72M687.41M614.30M503.01M
Gross Profit144.25M147.50M164.61M168.45M170.23M134.11M
EBITDA-45.88M-52.06M-75.65M-161.41M-214.71M-101.65M
Net Income-72.38M-83.05M-154.65M-241.97M-296.54M-196.43M
Balance Sheet
Total Assets1.11B1.26B1.40B934.45M946.85M954.64M
Cash, Cash Equivalents and Short-Term Investments703.42M797.70M822.67M351.76M364.91M419.87M
Total Debt520.84M574.47M603.44M573.44M456.28M446.23M
Total Liabilities785.76M892.31M964.28M1.38B1.21B1.09B
Stockholders Equity322.38M363.31M428.14M-451.98M-274.55M-132.99M
Cash Flow
Free Cash Flow36.20M21.56M-24.42M-81.17M-101.77M-124.13M
Operating Cash Flow35.91M21.56M-20.16M-73.83M-83.38M-17.30M
Investing Cash Flow-30.55M110.45M-146.60M-8.45M-5.47M-195.16M
Financing Cash Flow-93.62M-56.56M504.77M64.62M64.90M216.29M

NEUSOFT XIKANG HOLDINGS INC. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.91
Price Trends
50DMA
0.98
Negative
100DMA
0.96
Negative
200DMA
0.88
Positive
Market Momentum
MACD
>-0.01
Positive
RSI
28.30
Positive
STOCH
42.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9686, the sentiment is Negative. The current price of 0.91 is below the 20-day moving average (MA) of 0.98, below the 50-day MA of 0.98, and above the 200-day MA of 0.88, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 28.30 is Positive, neither overbought nor oversold. The STOCH value of 42.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9686.

NEUSOFT XIKANG HOLDINGS INC. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
HK$18.25B31.5724.57%0.89%13.58%24.59%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
HK$2.99B563.640.22%-4.38%
48
Neutral
HK$743.99M-20.60%11.43%4.88%
46
Neutral
HK$766.11M-20.43%
45
Neutral
HK$5.16B-2.97%-12.31%41.72%
40
Neutral
HK$1.31B-12.97%-32.17%-1.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.91
0.27
42.19%
HK:2158
Yidu Tech, Inc.
5.63
2.05
57.26%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.24
0.49
65.33%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.72
0.54
24.77%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
13.24
1.96
17.38%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
38.60
23.37
153.45%

NEUSOFT XIKANG HOLDINGS INC. Corporate Events

Xikang Cloud Hospital Holdings Reports Improved Losses Amid Revenue Dip
Aug 27, 2025

Xikang Cloud Hospital Holdings Inc. announced its interim results for the first half of 2025, reporting a slight revenue decrease of 0.3% compared to the same period in 2024, with a total revenue of RMB178.6 million. Despite the revenue dip, the company reduced its net loss by 17.4% to RMB50.0 million, attributed to business optimization and resource allocation improvements. The company’s unique business model, which involves strategic collaboration with local governments, aims to enhance the regional digital healthcare ecosystem through AI-driven innovations and scalable cloud hospital platforms.

The most recent analyst rating on (HK:9686) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on NEUSOFT XIKANG HOLDINGS INC. stock, see the HK:9686 Stock Forecast page.

Xikang Cloud Hospital Holdings to Discuss Interim Results and Dividend
Aug 15, 2025

Xikang Cloud Hospital Holdings Inc. has announced a board meeting scheduled for August 27, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, indicating a potential financial distribution to shareholders, which could impact investor sentiment and the company’s market positioning.

Xikang Cloud Hospital Grants Share Options to Boost Stakeholder Alignment
Jul 21, 2025

Xikang Cloud Hospital Holdings Inc. announced the grant of 28,990,000 share options to 236 eligible participants under its Post-IPO Share Option Scheme. The options, which have an exercise price of HK$0.904 per share, are subject to a vesting schedule over three years and performance targets based on financial and business-related indicators. The scheme includes a clawback mechanism for violations of laws or company rules, ensuring alignment with company goals and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 17, 2025